The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pneumococcal Bacteria Vaccine Market Research Report 2025
Synopsis
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
The global Pneumococcal Bacteria Vaccine market was valued at US$ 7200.2 million in 2023 and is anticipated to reach US$ 9692 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Bacteria Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Bacteria Vaccine.
Report Scope
The Pneumococcal Bacteria Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Bacteria Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Bacteria Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sanofi
Sinopharm
Pfizer
Walvax
GSK
Segment by Type
PPSV 23
PCV 13
PCV 10
Segment by Application
Infant
Children
Adult
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Bacteria Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Bacteria Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
The global Pneumococcal Bacteria Vaccine market was valued at US$ 7200.2 million in 2023 and is anticipated to reach US$ 9692 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Bacteria Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pneumococcal Bacteria Vaccine.
Report Scope
The Pneumococcal Bacteria Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Bacteria Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Bacteria Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sanofi
Sinopharm
Pfizer
Walvax
GSK
Segment by Type
PPSV 23
PCV 13
PCV 10
Segment by Application
Infant
Children
Adult
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pneumococcal Bacteria Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pneumococcal Bacteria Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pneumococcal Bacteria Vaccine Market Overview
1.1 Product Overview and Scope of Pneumococcal Bacteria Vaccine
1.2 Pneumococcal Bacteria Vaccine Segment by Type
1.2.1 Global Pneumococcal Bacteria Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 PPSV 23
1.2.3 PCV 13
1.2.4 PCV 10
1.3 Pneumococcal Bacteria Vaccine Segment by Application
1.3.1 Global Pneumococcal Bacteria Vaccine Market Value by Application: (2024-2030)
1.3.2 Infant
1.3.3 Children
1.3.4 Adult
1.4 Global Pneumococcal Bacteria Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pneumococcal Bacteria Vaccine Revenue 2019-2030
1.4.2 Global Pneumococcal Bacteria Vaccine Sales 2019-2030
1.4.3 Global Pneumococcal Bacteria Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pneumococcal Bacteria Vaccine Market Competition by Manufacturers
2.1 Global Pneumococcal Bacteria Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pneumococcal Bacteria Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Pneumococcal Bacteria Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pneumococcal Bacteria Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pneumococcal Bacteria Vaccine, Product Type & Application
2.7 Pneumococcal Bacteria Vaccine Market Competitive Situation and Trends
2.7.1 Pneumococcal Bacteria Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pneumococcal Bacteria Vaccine Players Market Share by Revenue
2.7.3 Global Pneumococcal Bacteria Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pneumococcal Bacteria Vaccine Retrospective Market Scenario by Region
3.1 Global Pneumococcal Bacteria Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pneumococcal Bacteria Vaccine Global Pneumococcal Bacteria Vaccine Sales by Region: 2019-2030
3.2.1 Global Pneumococcal Bacteria Vaccine Sales by Region: 2019-2024
3.2.2 Global Pneumococcal Bacteria Vaccine Sales by Region: 2025-2030
3.3 Global Pneumococcal Bacteria Vaccine Global Pneumococcal Bacteria Vaccine Revenue by Region: 2019-2030
3.3.1 Global Pneumococcal Bacteria Vaccine Revenue by Region: 2019-2024
3.3.2 Global Pneumococcal Bacteria Vaccine Revenue by Region: 2025-2030
3.4 North America Pneumococcal Bacteria Vaccine Market Facts & Figures by Country
3.4.1 North America Pneumococcal Bacteria Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pneumococcal Bacteria Vaccine Sales by Country (2019-2030)
3.4.3 North America Pneumococcal Bacteria Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pneumococcal Bacteria Vaccine Market Facts & Figures by Country
3.5.1 Europe Pneumococcal Bacteria Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pneumococcal Bacteria Vaccine Sales by Country (2019-2030)
3.5.3 Europe Pneumococcal Bacteria Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pneumococcal Bacteria Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pneumococcal Bacteria Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pneumococcal Bacteria Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pneumococcal Bacteria Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pneumococcal Bacteria Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pneumococcal Bacteria Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pneumococcal Bacteria Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Pneumococcal Bacteria Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pneumococcal Bacteria Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pneumococcal Bacteria Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pneumococcal Bacteria Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pneumococcal Bacteria Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pneumococcal Bacteria Vaccine Sales by Type (2019-2030)
4.1.1 Global Pneumococcal Bacteria Vaccine Sales by Type (2019-2024)
4.1.2 Global Pneumococcal Bacteria Vaccine Sales by Type (2025-2030)
4.1.3 Global Pneumococcal Bacteria Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Pneumococcal Bacteria Vaccine Revenue by Type (2019-2030)
4.2.1 Global Pneumococcal Bacteria Vaccine Revenue by Type (2019-2024)
4.2.2 Global Pneumococcal Bacteria Vaccine Revenue by Type (2025-2030)
4.2.3 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Pneumococcal Bacteria Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pneumococcal Bacteria Vaccine Sales by Application (2019-2030)
5.1.1 Global Pneumococcal Bacteria Vaccine Sales by Application (2019-2024)
5.1.2 Global Pneumococcal Bacteria Vaccine Sales by Application (2025-2030)
5.1.3 Global Pneumococcal Bacteria Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Pneumococcal Bacteria Vaccine Revenue by Application (2019-2030)
5.2.1 Global Pneumococcal Bacteria Vaccine Revenue by Application (2019-2024)
5.2.2 Global Pneumococcal Bacteria Vaccine Revenue by Application (2025-2030)
5.2.3 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Pneumococcal Bacteria Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Pneumococcal Bacteria Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Pneumococcal Bacteria Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Sinopharm
6.3.1 Sinopharm Corporation Information
6.3.2 Sinopharm Description and Business Overview
6.3.3 Sinopharm Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sinopharm Pneumococcal Bacteria Vaccine Product Portfolio
6.3.5 Sinopharm Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Pneumococcal Bacteria Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Walvax
6.5.1 Walvax Corporation Information
6.5.2 Walvax Description and Business Overview
6.5.3 Walvax Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Walvax Pneumococcal Bacteria Vaccine Product Portfolio
6.5.5 Walvax Recent Developments/Updates
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Pneumococcal Bacteria Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GSK Pneumococcal Bacteria Vaccine Product Portfolio
6.6.5 GSK Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pneumococcal Bacteria Vaccine Industry Chain Analysis
7.2 Pneumococcal Bacteria Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pneumococcal Bacteria Vaccine Production Mode & Process
7.4 Pneumococcal Bacteria Vaccine Sales and Marketing
7.4.1 Pneumococcal Bacteria Vaccine Sales Channels
7.4.2 Pneumococcal Bacteria Vaccine Distributors
7.5 Pneumococcal Bacteria Vaccine Customers
8 Pneumococcal Bacteria Vaccine Market Dynamics
8.1 Pneumococcal Bacteria Vaccine Industry Trends
8.2 Pneumococcal Bacteria Vaccine Market Drivers
8.3 Pneumococcal Bacteria Vaccine Market Challenges
8.4 Pneumococcal Bacteria Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
